Shares of Fluidigm FLDM fell in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 333.33% year over year to ($0.13), which missed the estimate of ($0.07).
Revenue of $44,608,000 up by 37.51% year over year, which missed the estimate of $50,720,000.
Guidance
Fluidigm Sees Q1 Sales $30M-$33M vs. $47.62M Est., FY21 Sales $144M-$155M Vs. $198.25M Est.
How To Listen To The Conference Call
Date: Feb 10, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/oq3jcsm6
Recent Stock Performance
52-week high: $12.45
52-week low: $1.17
Price action over last quarter: Up 16.53%
Company Description
Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.